Regranex MedWatch Cancer
FDA is investigating the potential for increased risk of death among diabetic patients receiving Johnson & Johnson's Regranex (becaplerim), FDA says in a March 27 MedWatch alert. In a study using a health insurance plan database of patients with diabetes with no history of cancer, among those who applied Regranex three or more times to foot and leg ulcers, there was an increase in the number of patients who died as a result of cancer. While evaluating the mortality signal, FDA is advising physicians to weigh the evidence for increased risk of death against the risks associated with diabetic foot and leg ulcers that do not heal...
You may also be interested in...
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.